treatment lung tumor In recent years, little progress has been made in the local advanced unoperable stadiums. Therefore, the Spanish Lung Cancer Group (GECP) Has been improving treatment options and avoiding high toxicity.
This Nora Research,who result Just published on Lung cancer, Confirmed benefits “Omics” chemotherapy In this group of patients: “It is not the intermittent and high-dose use of one or two drugs, but the combined use of them Low-dose various drugs Uninterrupted regime.This is another advance allowed Greatly reduce toxicity “The current treatment,” he explained to SINC Mariano Provencio, GECP Chairman and Lead Author”.
The researchers treated 65 patients Low-dose radiation therapy with two different drugs. Of the total number of people who completed the treatment, 66.2% responded to the treatment, and there was a total of 11 and a half months of disease-free survival.
In the entire treatment regimen, about 20.5% of patients had treatment-related adverse events, of which 3% (23% of the traditional mode of administration) developed esophagitis, and 1.5% (12% of the traditional regimen) developed pneumonia. And neutropenia in 6.2% of patients (54%).
“Using this low-dose method-world pioneer- Less risk of adverse reactionsProvenceio added that this method allows the treatment to continue to be equally effective and less harmful. “We got survival and disease progression results similar to standard treatment, but Reduce toxicity by about 80%“.
The future of liquid biopsy
The question is how these results can change the treatment of lung cancer.This work also evaluated Circulating tumor DNA levels (CtDNA) and survival rate, which is used for Liquid biopsy As a tool for monitoring treatment response.
Liquid biopsy or liquid biopsy is a new cancer diagnosis and monitoring technology. It consists of a blood test that can confirm or rule out the presence of tumor cells in the blood, and if so, can also analyze whether there are tumor cells in the blood. ADN The treatment can be personalized or adjusted.
After three months of follow-up, it was found that patients whose tumor DNA could not be detected had a longer survival period than those who remained positive at the time.
Provencio, head of oncology at Puerta de Hierro Hospital, said: “Our research provides a new solution to traditional therapies.” “It lays the foundation for liquid biopsy control for these patients and lays the foundation for future research.”
Mariano Provencio et al.: “Phase II clinical trial, using rhythmic oral vinorelbine and cisplatin three weeks a week as induction therapy, followed by radiotherapy (RT) for patients with locally advanced, unresectable non-small cell lung cancer.” Lung cancer